The budget impact of utilizing the Oncotype DX Breast Recurrence Score test from a US healthcare payer perspective

References

• Cancer.net. Breast Cancer: statistics [Internet]. 2022. https://www.cancer.net/cancer-types/breast-cancer/statistics#:∼:text=Sixty-five
   Google Scholar
• Redig AJ, Mcallister SS. Breast cancer as a systemic disease: a view of metastasis. J Intern Med. 2013;274(2):113–126. doi:10.1111/joim.12084.
   PubMed Web of Science ®Google Scholar
• Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PloS Med. 2010;7(5):e1000279. doi:10.1371/journal.pmed.1000279.
   PubMed Web of Science ®Google Scholar
• Howlader N, Cronin KA, Kurian AW, et al. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018;27(6):619–626. doi:10.1158/1055-9965.EPI-17-0627.
   PubMed Web of Science ®Google Scholar
• Biganzoli L, Wildiers H, Oakman C, et al. Management of elderly patients with breast cancer: updated recommendations of the international society of geriatric oncology (SIOG) and european society of breast cancer specialists (EUSOMA) [internet]. Lancet Oncol. 2012;13:e148–60. doi:10.1016/S1470-2045(11)70383-7.
   Google Scholar
• National Institute for Health and Care Excellence. Early and locally advanced breast cancer: diagnosis and management. 2018.
   Google Scholar
• National Comprehensive Cancer Network. NCCN Guidelines: breast Cancer, version 4.2022. 2022.
   Google Scholar
• National Institutes of Health Consensus Development Panel. National institutes of health consensus development conference statement: adjuvant therapy for breast cancer, november 1–3, 2000. JNCI J Natl Cancer Inst. 2001;93(13):979–989.
   Web of Science ®Google Scholar
• Ellis P, Barrett-Lee P, Johnson L, et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet. 2009;373(9676):1681–1692. doi:10.1016/S0140-6736(09)60740-6.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-Gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–121. doi:10.1056/NEJMoa1804710.
   PubMed Web of Science ®Google Scholar
• Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene assay to inform chemotherapy benefit in Node-Positive breast cancer. N Engl J Med. 2021;385(25):2336–2347.
   PubMed Web of Science ®Google Scholar
• Lux MP, Nabieva N, Hildebrandt T, et al. Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany. Breast. 2018;37:89–98. doi:10.1016/j.breast.2017.11.002.
   PubMed Web of Science ®Google Scholar
• Retèl V, Joore M, van ‘t Veer L, et al. Abstract P4-12-01: mammaPrint is cost-effective compared to clinical risk assessment in early stage breast cancer. Cancer Res [Internet]. 2018;78(4_Supplement):P4-12-01–P4-12-01. doi:10.1158/1538-7445.SABCS17-P4-12-01.
   Web of Science ®Google Scholar
• US Census Bureau. Current Population Survey, 2019 and 2021 Annual Social and Economic Supplement. 2020. https://www.census.gov/programs-surveys/cps/techdocs/cpsmar21.pdf
   Google Scholar
• U.S. Census Bureau. Population by age and sex [Internet]. 2019 https://data.census.gov/cedsci/
   Google Scholar
• National Cancer Institute. Female Breast Cancer—Cancer Stat Facts [Internet]. 2022. https://seer.cancer.gov/statfacts/html/breast.html
   Google Scholar
• DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019 Nov 1;69(6):438–451. doi:10.3322/caac.21583.
   PubMed Web of Science ®Google Scholar
• U.S. Census Bureau. American Community Survey 5-Year Estimates Subject Tables [Internet]. 2022. https://data.census.gov/cedsci/.
   Google Scholar
• National Cancer Institute. Cancer Stat Facts: female Breast Cancer [Internet]. 2022. https://seer.cancer.gov/statfacts/html/breast.html
   Google Scholar
• Nelson DR, Brown J, Morikawa A, et al. Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics. PloS One. 2022;17(2):e0264637. doi:10.1371/journal.pone.0264637.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Gray RJ, Ravdin PM, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019;380(25):2395–2405. doi:10.1056/NEJMoa1904819.
   PubMed Web of Science ®Google Scholar
• Roberts MC, Miller DP, Shak S, et al. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and oncotype DX recurrence score results in the SEER database. Breast Cancer Res Treat. 2017;163(2):303–310. doi:10.1007/s10549-017-4162-3.
   PubMed Web of Science ®Google Scholar
• Geyer CE, Tang G, Mamounas EP, et al. 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. NPJ Breast Cancer. 2018;4(1):37. doi:10.1038/s41523-018-0090-6.
   PubMedGoogle Scholar
• National Institute for Health and Care Excellence. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. 2018.
   Google Scholar
• Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65. doi:10.1016/S1470-2045(09)70314-6.
   PubMed Web of Science ®Google Scholar
• Kalinsky K. Predicting chemotherapy benefit in Node-Positive breast cancer with the 21-gene test: the oncotype DX breast recurrence score® test. In San Antonio Breast Cancer Conference, San Antonio, TA; 2021.
   Google Scholar
• Wang SY, Chen T, Dang W, et al. Incorporating tumor characteristics to maximize 21-Gene assay utility: a Cost-Effectiveness analysis. J Natl Compr Canc Netw. 2019;17(1):39–46. doi:10.6004/jnccn.2018.7077.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Borgonovo K, Cabiddu M, et al. Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis. Breast Cancer Res Treat. 2012;135(2):335–346. doi:10.1007/s10549-012-2121-6.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia. 2018.
   Google Scholar
• Kunst NR, Alarid-Escudero F, Paltiel AD, et al. A value of information analysis of research on the 21-Gene Assay for Breast Cancer Management. Value Health. 2019;22(1):1102–1110. doi:10.1016/j.jval.2019.05.004.
   PubMedGoogle Scholar
• Kurosky SK, Mitra D, Zanotti G, et al. Treatment patterns and outcomes of patients with metastatic ER+/HER-2- breast cancer: a multicountry retrospective medical record review. Clin Breast Cancer. 2018;18(4):e529–e538. doi:10.1016/j.clbc.2017.10.008
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. 2019.
   Google Scholar
• Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5. doi:10.1038/s41523-018-0097-z.
   PubMed Web of Science ®Google Scholar
• Choi IS, Jung J, Kim BH, et al. The 21-Gene recurrence score assay and prediction of chemotherapy benefit: a propensity Score-Matched analysis of the SEER database. Cancers (Basel) [Internet]. 2020 Jul 8;12(7):1829. doi:10.3390/cancers12071829.
   PubMed Web of Science ®Google Scholar
• Petkov VI, Miller DP, Howlader N, et al. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ Breast Cancer. 2016;2(1):16017. doi:10.1038/npjbcancer.2016.17.
   PubMedGoogle Scholar
• Noone AM, Lund JL, Mariotto A, et al. Comparison of SEER treatment data with medicare claims. Med Care. 2016;54(9):e55–64–e64.
   PubMed Web of Science ®Google Scholar
• Sestak I, Buus R, Cuzick J, et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor–positive breast cancer a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4(4):545–553. doi:10.1001/jamaoncol.2017.5524.
   PubMed Web of Science ®Google Scholar
• Arias E, Xu J. United States life tables. Natl Vital Stat Rep. 2020;69(12):1–45.
   Google Scholar
• OECD. Consumer price indices (CPIs) - Complete database [Internet]. 2021. https://stats.oecd.org/index.aspx?DataSetCode=PRICES_CPI.
   Google Scholar
• ICER. A Guide to ICER’s Methods for Health Technology Assessment. 2020;
   Google Scholar
• Henry J. Kaiser family foundation. Medicaid-to-Medicare Fee Index [Internet]. 2021. https://www.kff.org/medicaid/state-indicator/medicaid-to-medicare-fee-index/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D
   Google Scholar
• MedPAC. Medicare Payment Advisory Commission (MedPAC). Report to the Congress: medicare payment policy. 2019.
   Google Scholar
• Berdunov V, Millen S, Paramore A, et al. Cost-effectiveness analysis of the oncotype DX breast recurrence score test in node-positive early breast cancer. J Med Econ. 2022;25(1):591–604. doi:10.1080/13696998.2022.2066399.
   PubMed Web of Science ®Google Scholar
• Berdunov V, Carter GC, Laws E, et al. HSR22-129: the cost of treatment of HR+/HER2– Early breast cancer and implications for the Cost-Effectiveness of multigene assays in the US. J Natl Compr Cancer Netw. 2022;20(3.5):HSR22-129. doi:10.6004/jnccn.2021.7241.
   Google Scholar
• Albain KS, Gray RJ, Makower DF, et al. Race, ethnicity, and clinical outcomes in hormone Receptor-Positive, HER2-Negative, Node-Negative breast cancer in the randomized TAILORx trial. J Natl Cancer Inst. 2021;113(4):390–399. doi:10.1093/jnci/djaa148.
   PubMedGoogle Scholar
• Abdou Y, Barlow WE, Gralow JR, et al. Abstract GS1-01: race and clinical outcomes in the RxPONDER trial (SWOG S1007). Cancer Res. 2023;83(5_Supplement):GS1-01–GS1-01. doi:10.1158/1538-7445.SABCS22-GS1-01.
   Web of Science ®Google Scholar
• Holt S, Bertelli G, Humphreys I, et al. A decision impact, decision conflict and economic assessment of routine oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the U.K. Br J Cancer. 2013;108(11):2250–2258. doi:10.1038/bjc.2013.207.
   PubMed Web of Science ®Google Scholar
• Loncaster J, Armstrong A, Howell S, et al. Impact of oncotype DX breast recurrence score testing on adjuvant chemotherapy use in early breast cancer: real world experience in greater Manchester, UK. Eur J Surg Oncol. 2017;43(5):931–937. doi:10.1016/j.ejso.2016.12.010.
   PubMed Web of Science ®Google Scholar
• Hornberger J, Chien R, Krebs K, et al. US insurance program’s experience with a multigene assay for early-stage breast cancer. J Oncol Pract. 2011;7(3 SUPPL):e38s–e45s.
   PubMedGoogle Scholar
• Hochheiser L, Hornberger J, Turner M, et al. Multi-gene assays: effect on chemotherapy use, toxicity and cost in estrogen receptor-positive early stage breast cancer. J Comp Eff Res. 2019;8(5):289–304. doi:10.2217/cer-2018-0137.
   PubMed Web of Science ®Google Scholar
• Dinan MA, Wilson LE, Reed SD. Chemotherapy costs and 21-Gene recurrence score genomic testing among medicare beneficiaries with Early-Stage breast cancer, 2005 to 2011. J Natl Compr Canc Netw. 2019;17(3):245–254. doi:10.6004/jnccn.2018.7097.
   PubMed Web of Science ®Google Scholar
• Bhargava R, Esposito NN, O′Connor SM, et al. Magee EquationsTM and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study. Mod Pathol. 2021;34(1):77–84. doi:10.1038/s41379-020-0620-2.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Crager MR, Tang G, et al. Development and validation of a tool integrating the 21-Gene recurrence score and Clinical-Pathological features to individualize prognosis and prediction of chemotherapy benefit in early breast cancer. J Clin Oncol. 2021;39(6):557–564. doi:10.1200/JCO.20.03007.
   PubMed Web of Science ®Google Scholar